Surrozen (SRZN) Competitors

$29.98 -0.17 (-0.55%)

As of 03:26 PM Eastern

SRZN vs. ABCL, MBX, WVE, AVBP, and KALV

Should you buy Surrozen stock or one of its competitors? MarketBeat compares Surrozen with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Surrozen include AbCellera Biologics (ABCL), MBX Biosciences (MBX), WAVE Life Sciences (WVE), ArriVent BioPharma (AVBP), and KalVista Pharmaceuticals (KALV). These companies are all part of the "pharmaceutical products" industry.

How does Surrozen compare to AbCellera Biologics?

AbCellera Biologics (NASDAQ:ABCL) and Surrozen (NASDAQ:SRZN) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, profitability, dividends, valuation, institutional ownership, analyst recommendations, earnings and risk.

In the previous week, Surrozen had 13 more articles in the media than AbCellera Biologics. MarketBeat recorded 23 mentions for Surrozen and 10 mentions for AbCellera Biologics. AbCellera Biologics' average media sentiment score of 0.72 beat Surrozen's score of 0.32 indicating that AbCellera Biologics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AbCellera Biologics	1 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Surrozen	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

AbCellera Biologics has higher revenue and earnings than Surrozen. AbCellera Biologics is trading at a lower price-to-earnings ratio than Surrozen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AbCellera Biologics	$79.21M	17.18	-$146.41M	-$0.48	N/A
Surrozen	$3.48M	98.97	-$242.03M	-$37.59	N/A

AbCellera Biologics currently has a consensus price target of $8.17, indicating a potential upside of 83.31%. Surrozen has a consensus price target of $42.00, indicating a potential upside of 40.12%. Given AbCellera Biologics' higher possible upside, equities analysts clearly believe AbCellera Biologics is more favorable than Surrozen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AbCellera Biologics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
Surrozen	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

AbCellera Biologics has a net margin of -181.75% compared to Surrozen's net margin of -4,810.50%. AbCellera Biologics' return on equity of -14.86% beat Surrozen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AbCellera Biologics	-181.75%	-14.86%	-10.62%
Surrozen	-4,810.50%	-4,055.04%	-154.08%

61.4% of AbCellera Biologics shares are owned by institutional investors. Comparatively, 66.6% of Surrozen shares are owned by institutional investors. 28.4% of AbCellera Biologics shares are owned by company insiders. Comparatively, 31.7% of Surrozen shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

AbCellera Biologics has a beta of 1.02, meaning that its stock price is 2% more volatile than the broader market. Comparatively, Surrozen has a beta of 0.59, meaning that its stock price is 41% less volatile than the broader market.

Summary

AbCellera Biologics beats Surrozen on 10 of the 16 factors compared between the two stocks.

How does Surrozen compare to MBX Biosciences?

MBX Biosciences (NASDAQ:MBX) and Surrozen (NASDAQ:SRZN) are both small-cap pharmaceutical products companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, media sentiment, dividends, institutional ownership, risk, valuation, analyst recommendations and earnings.

66.6% of Surrozen shares are owned by institutional investors. 52.2% of MBX Biosciences shares are owned by insiders. Comparatively, 31.7% of Surrozen shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, MBX Biosciences had 7 more articles in the media than Surrozen. MarketBeat recorded 30 mentions for MBX Biosciences and 23 mentions for Surrozen. MBX Biosciences' average media sentiment score of 0.78 beat Surrozen's score of 0.32 indicating that MBX Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MBX Biosciences	6 Very Positive mention(s)	7 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Surrozen	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

MBX Biosciences has higher earnings, but lower revenue than Surrozen. MBX Biosciences is trading at a lower price-to-earnings ratio than Surrozen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MBX Biosciences	N/A	N/A	-$86.97M	-$2.21	N/A
Surrozen	$3.48M	98.97	-$242.03M	-$37.59	N/A

MBX Biosciences has a net margin of 0.00% compared to Surrozen's net margin of -4,810.50%. MBX Biosciences' return on equity of -24.52% beat Surrozen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MBX Biosciences	N/A	-24.52%	-23.59%
Surrozen	-4,810.50%	-4,055.04%	-154.08%

MBX Biosciences currently has a consensus price target of $60.22, indicating a potential upside of 67.98%. Surrozen has a consensus price target of $42.00, indicating a potential upside of 40.12%. Given MBX Biosciences' higher probable upside, equities research analysts clearly believe MBX Biosciences is more favorable than Surrozen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MBX Biosciences	2 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.77
Surrozen	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

MBX Biosciences has a beta of 0.78, meaning that its share price is 22% less volatile than the broader market. Comparatively, Surrozen has a beta of 0.59, meaning that its share price is 41% less volatile than the broader market.

Summary

MBX Biosciences beats Surrozen on 11 of the 15 factors compared between the two stocks.

How does Surrozen compare to WAVE Life Sciences?

WAVE Life Sciences (NASDAQ:WVE) and Surrozen (NASDAQ:SRZN) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, media sentiment, dividends, institutional ownership, risk, valuation, analyst recommendations and earnings.

WAVE Life Sciences has a beta of -1.32, meaning that its share price is 232% less volatile than the broader market. Comparatively, Surrozen has a beta of 0.59, meaning that its share price is 41% less volatile than the broader market.

In the previous week, Surrozen had 20 more articles in the media than WAVE Life Sciences. MarketBeat recorded 23 mentions for Surrozen and 3 mentions for WAVE Life Sciences. WAVE Life Sciences' average media sentiment score of 0.69 beat Surrozen's score of 0.32 indicating that WAVE Life Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
WAVE Life Sciences	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Surrozen	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

89.7% of WAVE Life Sciences shares are owned by institutional investors. Comparatively, 66.6% of Surrozen shares are owned by institutional investors. 24.3% of WAVE Life Sciences shares are owned by insiders. Comparatively, 31.7% of Surrozen shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

WAVE Life Sciences has a net margin of -255.70% compared to Surrozen's net margin of -4,810.50%. WAVE Life Sciences' return on equity of -56.76% beat Surrozen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
WAVE Life Sciences	-255.70%	-56.76%	-42.80%
Surrozen	-4,810.50%	-4,055.04%	-154.08%

WAVE Life Sciences currently has a consensus price target of $27.50, indicating a potential upside of 295.97%. Surrozen has a consensus price target of $42.00, indicating a potential upside of 40.12%. Given WAVE Life Sciences' stronger consensus rating and higher probable upside, equities research analysts clearly believe WAVE Life Sciences is more favorable than Surrozen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
WAVE Life Sciences	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.87
Surrozen	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

WAVE Life Sciences has higher revenue and earnings than Surrozen. WAVE Life Sciences is trading at a lower price-to-earnings ratio than Surrozen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
WAVE Life Sciences	$71.80M	18.61	-$204.38M	-$1.06	N/A
Surrozen	$3.48M	98.97	-$242.03M	-$37.59	N/A

Summary

WAVE Life Sciences beats Surrozen on 11 of the 17 factors compared between the two stocks.

How does Surrozen compare to ArriVent BioPharma?

Surrozen (NASDAQ:SRZN) and ArriVent BioPharma (NASDAQ:AVBP) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, media sentiment, institutional ownership, profitability, earnings and risk.

Surrozen has a beta of 0.59, meaning that its share price is 41% less volatile than the broader market. Comparatively, ArriVent BioPharma has a beta of 1.51, meaning that its share price is 51% more volatile than the broader market.

ArriVent BioPharma has lower revenue, but higher earnings than Surrozen. ArriVent BioPharma is trading at a lower price-to-earnings ratio than Surrozen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Surrozen	$3.48M	98.97	-$242.03M	-$37.59	N/A
ArriVent BioPharma	N/A	N/A	-$166.31M	-$3.47	N/A

In the previous week, Surrozen had 14 more articles in the media than ArriVent BioPharma. MarketBeat recorded 23 mentions for Surrozen and 9 mentions for ArriVent BioPharma. Surrozen's average media sentiment score of 0.32 beat ArriVent BioPharma's score of -0.33 indicating that Surrozen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Surrozen	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
ArriVent BioPharma	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

66.6% of Surrozen shares are owned by institutional investors. Comparatively, 9.5% of ArriVent BioPharma shares are owned by institutional investors. 31.7% of Surrozen shares are owned by company insiders. Comparatively, 8.6% of ArriVent BioPharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

ArriVent BioPharma has a net margin of 0.00% compared to Surrozen's net margin of -4,810.50%. ArriVent BioPharma's return on equity of -48.98% beat Surrozen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Surrozen	-4,810.50%	-4,055.04%	-154.08%
ArriVent BioPharma	N/A	-48.98%	-45.44%

Surrozen presently has a consensus price target of $42.00, suggesting a potential upside of 40.12%. ArriVent BioPharma has a consensus price target of $42.78, suggesting a potential upside of 47.82%. Given ArriVent BioPharma's stronger consensus rating and higher possible upside, analysts clearly believe ArriVent BioPharma is more favorable than Surrozen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Surrozen	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
ArriVent BioPharma	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.92

Summary

ArriVent BioPharma beats Surrozen on 10 of the 16 factors compared between the two stocks.

How does Surrozen compare to KalVista Pharmaceuticals?

Surrozen (NASDAQ:SRZN) and KalVista Pharmaceuticals (NASDAQ:KALV) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, media sentiment, institutional ownership, profitability, earnings and risk.

66.6% of Surrozen shares are owned by institutional investors. 31.7% of Surrozen shares are owned by company insiders. Comparatively, 4.3% of KalVista Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Surrozen presently has a consensus price target of $42.00, suggesting a potential upside of 40.12%. KalVista Pharmaceuticals has a consensus price target of $30.60, suggesting a potential upside of 14.29%. Given Surrozen's stronger consensus rating and higher possible upside, equities research analysts clearly believe Surrozen is more favorable than KalVista Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Surrozen	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
KalVista Pharmaceuticals	1 Sell rating(s)	5 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.22

KalVista Pharmaceuticals has lower revenue, but higher earnings than Surrozen. KalVista Pharmaceuticals is trading at a lower price-to-earnings ratio than Surrozen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Surrozen	$3.48M	98.97	-$242.03M	-$37.59	N/A
KalVista Pharmaceuticals	$1.43M	961.76	-$109.52M	-$3.95	N/A

In the previous week, Surrozen had 18 more articles in the media than KalVista Pharmaceuticals. MarketBeat recorded 23 mentions for Surrozen and 5 mentions for KalVista Pharmaceuticals. KalVista Pharmaceuticals' average media sentiment score of 0.55 beat Surrozen's score of 0.32 indicating that KalVista Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Surrozen	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
KalVista Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

KalVista Pharmaceuticals has a net margin of 0.00% compared to Surrozen's net margin of -4,810.50%. KalVista Pharmaceuticals' return on equity of -214.88% beat Surrozen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Surrozen	-4,810.50%	-4,055.04%	-154.08%
KalVista Pharmaceuticals	N/A	-214.88%	-81.87%

Surrozen has a beta of 0.59, meaning that its share price is 41% less volatile than the broader market. Comparatively, KalVista Pharmaceuticals has a beta of -0.12, meaning that its share price is 112% less volatile than the broader market.

Summary

Surrozen beats KalVista Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

Get Surrozen News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SRZN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SRZN vs. The Competition

Export

Metric	Surrozen	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$344.41M	$3.04B	$6.29B	$12.46B
Dividend Yield	N/A	1.96%	2.79%	5.30%
P/E Ratio	-0.80	18.81	20.85	25.56
Price / Sales	98.97	279.58	543.57	72.25
Price / Cash	N/A	56.53	42.94	55.34
Price / Book	-1.24	4.36	9.87	6.72
Net Income	-$242.03M	$72.19M	$3.55B	$333.62M
7 Day Performance	-2.52%	-0.61%	-0.23%	0.35%
1 Month Performance	-5.89%	0.34%	1.47%	4.00%
1 Year Performance	361.15%	46.24%	41.05%	36.32%

Surrozen Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SRZN Surrozen	3.5028 of 5 stars	$29.98 -0.5%	$42.00 +40.1%	+318.6%	$344.41M	$3.48M	N/A	80	Analyst Revision
ABCL AbCellera Biologics	3.1314 of 5 stars	$4.75 +1.9%	$8.17 +72.0%	+127.1%	$1.45B	$75.13M	N/A	500	Earnings Report Gap Up
MBX MBX Biosciences	3.544 of 5 stars	$29.73 +0.4%	$53.25 +79.1%	N/A	$1.41B	N/A	N/A	N/A	Analyst Forecast Analyst Revision
WVE WAVE Life Sciences	2.7611 of 5 stars	$7.20 +0.2%	$27.50 +282.2%	+9.4%	$1.38B	$42.73M	N/A	240
AVBP ArriVent BioPharma	2.567 of 5 stars	$29.64 -0.6%	$43.00 +45.1%	+51.5%	$1.37B	N/A	N/A	40	Earnings Report Analyst Forecast Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SRZN) was last updated on 5/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Surrozen (SRZN) Competitors

SRZN vs. ABCL, MBX, WVE, AVBP, and KALV

How does Surrozen compare to AbCellera Biologics?

Summary

How does Surrozen compare to MBX Biosciences?

Summary

How does Surrozen compare to WAVE Life Sciences?

Summary

How does Surrozen compare to ArriVent BioPharma?

Summary

How does Surrozen compare to KalVista Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SRZN vs. The Competition

Surrozen Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Surrozen (SRZN) Competitors

SRZN vs. ABCL, MBX, WVE, AVBP, and KALV

How does Surrozen compare to AbCellera Biologics?

Does the media refer more to ABCL or SRZN?

Which has better earnings & valuation, ABCL or SRZN?

Do analysts prefer ABCL or SRZN?

Is ABCL or SRZN more profitable?

Do insiders & institutionals have more ownership in ABCL or SRZN?

Which has more volatility & risk, ABCL or SRZN?

Summary

How does Surrozen compare to MBX Biosciences?

Do insiders & institutionals hold more shares of MBX or SRZN?

Does the media refer more to MBX or SRZN?

Which has stronger valuation and earnings, MBX or SRZN?

Is MBX or SRZN more profitable?

Do analysts prefer MBX or SRZN?

Which has more volatility and risk, MBX or SRZN?

Summary

How does Surrozen compare to WAVE Life Sciences?

Which has more volatility and risk, WVE or SRZN?

Does the media refer more to WVE or SRZN?

Do insiders & institutionals hold more shares of WVE or SRZN?

Is WVE or SRZN more profitable?

Do analysts prefer WVE or SRZN?

Which has stronger valuation and earnings, WVE or SRZN?

Summary

How does Surrozen compare to ArriVent BioPharma?

Which has more volatility and risk, SRZN or AVBP?

Which has better valuation & earnings, SRZN or AVBP?

Does the media favor SRZN or AVBP?

Do insiders and institutionals hold more shares of SRZN or AVBP?

Is SRZN or AVBP more profitable?

Do analysts recommend SRZN or AVBP?

Summary

How does Surrozen compare to KalVista Pharmaceuticals?

Do insiders and institutionals hold more shares of SRZN or KALV?

Do analysts recommend SRZN or KALV?

Which has better valuation & earnings, SRZN or KALV?

Does the media favor SRZN or KALV?

Is SRZN or KALV more profitable?

Which has more volatility and risk, SRZN or KALV?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SRZN vs. The Competition

Surrozen Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools